Transformation of ALK rearrangement-positive adenocarcinoma to small-cell lung cancer in association with acquired resistance to alectinib

Ann Oncol. 2016 May;27(5):953-5. doi: 10.1093/annonc/mdw032. Epub 2016 Jan 24.

Authors

N Takegawa¹, H Hayashi², N Iizuka³, T Takahama¹, H Ueda¹, K Tanaka¹, M Takeda¹, K Nakagawa¹

Affiliations

¹ Department of Medical Oncology, Kinki University Faculty of Medicine, Osaka-Sayama.
² Department of Medical Oncology, Kinki University Faculty of Medicine, Osaka-Sayama hayashi_h@dotd.med.kindai.ac.jp.
³ Department of Pathology, Kishiwada City Hospital, Kishiwada, Japan.

PMID: 26811347
DOI: 10.1093/annonc/mdw032

No abstract available

Publication types

Case Reports
Letter
Comment

MeSH terms

Adenocarcinoma / drug therapy*
Adenocarcinoma / genetics
Adenocarcinoma / pathology
Adult
Anaplastic Lymphoma Kinase
Carbazoles / pharmacology
Carbazoles / therapeutic use*
Cell Transformation, Neoplastic / drug effects
Cell Transformation, Neoplastic / genetics
Cell Transformation, Neoplastic / pathology
Disease Progression
Drug Resistance, Neoplasm / drug effects*
Drug Resistance, Neoplasm / genetics
Female
Humans
Lung Neoplasms / drug therapy*
Lung Neoplasms / genetics
Lung Neoplasms / pathology
Piperidines / pharmacology
Piperidines / therapeutic use*
Protein Kinase Inhibitors / pharmacology
Protein Kinase Inhibitors / therapeutic use
Receptor Protein-Tyrosine Kinases* / genetics
Small Cell Lung Carcinoma / drug therapy*
Small Cell Lung Carcinoma / genetics
Small Cell Lung Carcinoma / pathology

Substances

Carbazoles
Piperidines
Protein Kinase Inhibitors
ALK protein, human
Anaplastic Lymphoma Kinase
Receptor Protein-Tyrosine Kinases
alectinib